Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gazzah, Anas, Gonzales, Daniel Barrios, Levy, Antonin, Bahleda, Rastislav, Ducreux, Michel, Lacroix, Ludovic, Soria, Jean Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581357/
https://www.ncbi.nlm.nih.gov/pubmed/23450148
http://dx.doi.org/10.2147/OTT.S38520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581357/
https://www.ncbi.nlm.nih.gov/pubmed/23450148
http://dx.doi.org/10.2147/OTT.S38520

Ejemplares similares